MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 22, 2007; DOI: 10.1124/mol.107.034058


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.034058v1
72/5/1322    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Twede, V. D
Right arrow Articles by Bamber, B. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Twede, V. D
Right arrow Articles by Bamber, B. A


Received for publication January 10, 2007.
Revised August 14, 2007.
Accepted for publication August 22, 2007.

The neurosteroids dehydroepiandrosterone sulfate and pregnenolone sulfate inhibit the UNC-49 GABA receptor through a common set of residues

Vernon D Twede 1, Douglas F Covey 2, Anthony L Tartaglia 3, Bruce A Bamber 3*

1 University of Utah 2 Washington University in St. Louis 3 University of Toledo

* Address correspondence to: E-mail: bruce.bamber{at}utoledo.edu

Abstract

Neurosteroids are endogenous neuromodulators that bind and allosterically regulate GABAA receptors. Residues were recently identified in the first transmembrane domain (M1) of GABAA receptor subunits that are important for neurosteroid modulation. We are studying the inhibition of GABAA receptors by sulfated neurosteroids. One of these, pregnenolone sulfate (PS), depends on six identified M1 residues to inhibit the UNC-49 GABA receptor, a homomeric GABA receptor from Caenorhabditis elegans that is homologous to the mammalian GABAA receptor. Here, we investigate the inhibition of the UNC-49 GABA receptor by another sulfated neurosteroid, dehydroepiandrosterone sulfate (DHEAS). DHEAS is identical to PS except that it contains a carbonyl oxygen instead of an acetyl group at C17 on the steroid D ring. UNC-49 mutations that affect PS inhibition had broadly parallel effects on DHEAS, suggesting the two neurosteroids act through similar mechanisms. However certain M1 mutations affected DHEAS differently than PS. Considering that first, the D ring contains the only structural difference between PS and DHEAS, and second, the strongest chemical and steric effects of a mutation are likely to be felt in the local environment of the altered residues, this result implies that the steroid D ring may contact M1 near the mutated residues. This possibility is interesting because current models of neurosteroid interactions with GABAA receptors, based on pregnane steroids, suggest that the steroid A ring binds M1, while the D ring binds M4. Our findings suggest that there may be considerable diversity in the way different classes of neurosteroids interact with GABAA receptors.


Key words: GABAA, GABAC, Chloride, Structure-activity relationships and modeling, Func. analysis receptor/ion channel mutants, Synaptic plasticity





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics